Bone health in adults with epilepsy

Acta Neurologica Scandinavica

Volumn 124, Issue SUPPL. 191, 2011, Pages 89-95

  Svalheim, S ^a   Roste L S ^a   Nakken, K O ^b   Tauboll E ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Antiepileptic drugs; Bone mineral density; Calcium; Fractures; Osteoporosis; Vitamin D

Indexed keywords

ALUMINUM; ANTACID AGENT; CALCITONIN; CALCIUM; CARBAMAZEPINE; GLUCOCORTICOID; HEPARIN; LITHIUM; PARATHYROID HORMONE; PHENOBARBITAL; PHENYTOIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; VALPROIC ACID; VITAMIN D;

BONE; BONE DENSITY; BONE MASS; BONE STRUCTURE; CLINICAL ASSESSMENT; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; EPILEPSY; FRACTURE; HEALTH; HIGH RISK PATIENT; HUMAN; LONG TERM EXPOSURE; OSTEOLYSIS; OSTEOPOROSIS; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; SEIZURE;

EID: 79960064598     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2011.01551.x     Document Type: Review

References (32)

1. Sander JW. The epidemiology of epilepsy revisited. Curr Opin Neurol 2003;16:165-70.
2. Vestergaard P. Epilepsy, osteoporosis and fracture risk - meta-analysis. Acta Neurol Scand 2005;112:277-86.
3. Pack A. Bone health in people with epilepsy: is it impaired and what are the risk factors? Seizure 2008;17:181-6.
4. Lofthus CM, Osnes EK, Falck JA et al. Epidemiology of hip fractures in Oslo, Norway. Bone 2001;29:413-8.
5. Epilepsy Action (UK). Anti-epileptic drugs and the risk of osteoporosis and osteomalcia: how much information do patients taking anti-epileptic drugs feel they receive about side effects of this medication? Leeds, UK: British Epilepsy Association, 2003.
6. Waters KS, Gonadal TC. Steroids and Receptors. In: Favus M, ed. Primer on the metabolic bone diseases and disorders of bone and mineral metabolism. New York: Lippincott Williams and Wilkins, 2006;104-10.
7. Sheth RD. Bone health in epilepsy. Lancet Neurol 2004;3:516.
8. Pothiwala P, Evans EM, Chapman-Novakofski KM. Ethnic variation in risk for osteoporosis among women: a review of biological and behavioral factors. J Womens Health (Larchmt) 2006;15:709-19.
9. Elliot ME, Binkley N. Evaluation and measurement of bone mass. Epilepsy Behav 2004;5:S16-23.
10. Kanis JA, Black B, Cooper C et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 2002;13:527-36.
11. Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 2004;5:S36-40.
12. Desai KB, Ribbans WJ, Taylor GJ. Incidence of five common fracture types in an institutional epileptic population. Injury 1996;27:97-100.
13. Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 2002;43:768-72.
14. Vestergaard P, Rejnmark L, Moeskilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004;45:1330-7.
15. Stephen LJ, Mclellan AR, Harrison JH et al. Bone density and antiepileptic drugs: a case-controlled study. Seizure 1999;8:339-42.
16. Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006;66:1318-24.
17. Phabphal K, Geater A, Leelawattana R, Sathirapunya P, Sattawatcharawanich S, Limapichat K. Prevalence and risk factors of low bone mineral density and 25-hydroxyvitamin D status in young healthy epileptic adult patients in a tropical Asian country taking antiepileptic drugs. Bone 2009;45:232-7.
18. Lyngstad-Brechan MA, Taubøll E, Nakken KO et al. Reduced bone mass and increased bone turnover in post menopausal women with epilepsy using antiepileptic drug monotherapy. Scand J Clin Lab Invest 2008;68:759-66.
19. Pack AM, Walczak TS. Bone health in women with epilepsy: clinical features and potential mechanisms. Int Rev Neurobiol 2008;83:305-28.
20. Pack AL, Morrell MJ, Marcus R et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005;57:252-7.
21. Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 2002;43:1488-92.
22. Verrotti A, Greco R, Morgese G, Chiarelli FA. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 2000;47:385-8.
23. Nakken KO, Taubøll E. Bone loss associated with use of antiepileptic drugs. Expert Opin Drug Saf 2010;9:561-71.
24. Onodera K, Takahashi A, Sakurada S, Okano Y. Effects of phenytoin and/or vitamin K2 (menatetrenone) on bone mineral density in the tibiae of growing rats. Life Sci 2002;70:1533-42.
25. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 2004;62:2051-7.
26. Petty SJ, O'brien TJ, Wark JD. Anti-epileptic medication and bone health. Osteoporos Int 2007;18:129-42.
27. Nissen-Meyer LSH, Svalheim S, Taubøll E et al. Levetiracetam, phenytoin and valproate act differently on rat bone mass, structure and metabolism. Epilepsia 2007;48:1850-60.
28. Apeland T, Mansoor M, Strandjord RE. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res 2001;47:27-35.
29. Nakken KO. Physical exercise in outpatients with epilepsy. Epilepsia 1999;40:643-51.
30. Convulsive disorders and participation in sports and physical education. JAMA 1968;206:1291.
31. ILAE Commission report. Restrictions for children with epilepsy. Commission of Pediatrics of the ILAE. International League Against Epilepsy. Epilepsia 1997;38:1054-6.
32. Røste LS, Taubøll E. Women and epilepsy: review and practical recommendations. Expert Rev Neurother 2007;7:289-300.